Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study

Anagnostis, Panagiotis; Selalmatzidou, Despina; Polyzos, Stergios A.; Panagiotou, Athanasios; Slavakis, Aristidis; Panagiotidou, A.E.; Athyros, Vasilios G.; Karagiannis, Asterios; Mikhailidis, Dimitri P.; Kita, Marina

doi:10.1111/j.1742-1241.2011.02655.x

Cited by 39 publications

(21 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The statin was discontinued and the subjects were withdrawn from the study in case of drug intolerance, pregnancy, AST and/or ALT elevation >3x or CK >10x the upper limit of normal range. We used some serum samples from patients from our previously published study [14], kept at -27 0 C, if they fulfilled the present study’s criteria. We further extended the study by enrolling 19 patients (during the same seasonal period).…”

Section: Methodsmentioning

confidence: 99%

Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study

Anagnostis¹,

Adamidou²,

Slavakis³

et al. 2014

TOCMJ

View full text Add to dashboard Cite

Aims: Low 25-hydroxy-vitamin D [25(ΟΗ)D] levels have been associated with increased risk for cardiovascular disease. Conflicting data exist regarding the effect of statins on [25(OH)D] levels. The aim of this study was to compare the effect of atorvastatin and rosuvastatin on 25(OH)D levels in non-diabetic patients with dyslipidaemia.Methods: This was a prospective randomized open-label study. Patients were assigned to atorvastatin 20 mg⁄day (n=28, age: 56.1±2.2 years, 22 females) or rosuvastatin 10 mg⁄day (n=24, age: 57.4±1.9 years, 20 females). Total cholesterol (TC), low- (LDL-C) and high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), fasting plasma glucose, insulin, glycosylated haemoglobin A1c (HbA1c) and high sensitivity C-reactive protein (hsCRP) levels were measured, and homeostatic model of assessment insulin resistance (HOMA-IR) was calculated at baseline and 12 weeks post-treatment. Results: There were no within or between group significant differences in 25(OH)D levels (atorvastatin: 21.7±1.9 ng/ml at baseline and 23.5±2.3 ng/ml at week 12; rosuvastatin: 25.3±1.8 and 27.0±2.4 ng/ml, respectively; p=0.172 and p=0.306 for between groups, respectively). Both statins significantly reduced TC, TG and LDL-C levels, with a greater LDL-C reduction being observed by rosuvastatin. Conclusion: Atorvastatin and rosuvastatin did not significantly affect 25(OH)D levels in this study.

show abstract

Section: Methodsmentioning

confidence: 99%

Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study

Anagnostis¹,

Adamidou²,

Slavakis³

et al. 2014

TOCMJ

View full text Add to dashboard Cite

show abstract

“…A high dose of atorvastatin (80 mg/day) resulted in increases in insulin levels and glycated albumin after 6-week treatment 36) . A lower dose of atorvastatin (20 mg per day) did not alter insulin concentrations, HOMA-IR, or HbA1c after 12-week treatment 37) . In another trial of an 8-week treatment 38) , however, atorvastatin (20 mg per day) resulted in a 3.0% increase in HbA1c, while no such increase was noted with rosuvastatin (10 mg/ day).…”

Section: Discussionmentioning

confidence: 81%

Effects of Pravastatin and Atorvastatin on HDL Cholesterol and Glucose Metabolism in Patients with Dyslipidemia and Glucose Intolerance: The PRAT Study

Sasaki¹,

Otonari²,

Uchida³

et al. 2013

JAT

View full text Add to dashboard Cite

Aims: While statins have the property of increasing high-density lipoprotein cholesterol (HDL-C) in addition to lowering low-density lipoprotein cholesterol (LDL-C), a potential adverse effect on glucose metabolism has raised a concern over statin therapy. In a comparative trial, we investigated the effects of low-dose pravastatin and atorvastatin on HDL-C and glucose metabolism in patients with elevated LDL-C levels and glucose intolerance. Methods: Eligible patients were men aged ≥ 20 years or postmenopausal women who had LDL-C ≥ 140 mg/dL, HDL-C ＜80 mg/dL, and triglycerides ＜500 mg/dL and who had glucose intolerance. The patients were randomly allocated to either pravastatin (10 mg/day) or atorvastatin (10 mg/day) treatment for 12 months in an unblinded fashion. The percent changes from the baseline were compared between the treatments. Results: Of 202 patients who were randomized to either of the two treatments, 195 patients started the study medication, and 187 patients underwent the follow-up measurements at 6 or 12 months (pravastatin, n= 93; atorvastatin, n = 94). HDL-C increased by 4.3% (p = 0.03) in the pravastatin group and by 5.8% (p= 0.0005) in the atorvastatin group and showed no between-group difference (p= 0.38). LDL-C decreased substantially in both groups (pravastatin, 21.5%; atorvastatin, 35.5%), and the decrease was much greater in the atorvastain group (p＜0.0001). HbA1c slightly increased in both groups, but showed no measurable difference in the increase between the two treatments (p = 0.30). Conclusion: Pravastatin and atorvastatin of 10 mg per day each increased HDL-C by almost the same extent. These two statins did not show a differential effect on glucose metabolism. J Atheroscler Thromb, 2013; 20:368-379.

show abstract

“…Por su parte, la atorvastatina no tuvo efecto sobre estos parámetros. Ninguna de estas estatinas alteró la glicemia en ayunas, el porcentaje de hemoglobina glicosilada ni los niveles de adiponectina 20 . Dado los disímiles resultados expuestos en el párrafo anterior, se ha reportado un meta-análisis que intenta evaluar en forma global el efecto de las estatinas sobre la RI.…”

Section: Las Estatinas Inducen Resistencia a Insulina En Estudios Clíunclassified

Riesgo de diabetes mellitus tipo 2 asociado al uso de estatinas: evidencias y posibles mecanismos

Suazo

Rigotti

2014

Rev. méd. Chile

View full text Add to dashboard Cite

Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study

Abstract: Rosuvastatin compared with atorvastatin resulted in significant improvements in IS indices. No significant changes in adiponectin, leptin or hsCRP levels were observed at 4 and 12 weeks of treatment with either statin.

Cited by 39 publications

References 31 publications

Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study

Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study

Effects of Pravastatin and Atorvastatin on HDL Cholesterol and Glucose Metabolism in Patients with Dyslipidemia and Glucose Intolerance: The PRAT Study

Riesgo de diabetes mellitus tipo 2 asociado al uso de estatinas: evidencias y posibles mecanismos

Contact Info

Product

Resources

About